Foghorn Therapeutics

Historical price data

Foghorn Therapeutics is a clinical-stage biotechnology company developing novel therapeutics targeting the chromatin regulatory system, a key driver in over half of all cancers. Its mission is to create precision medicines by selectively modulating chromatin remodeling complexes, such as the BAF complex, to address genetically determined dependencies in diseased cells. The company's strategy is powered by its integrated Gene Traffic Control® platform, which enables target identification, validation, and drug discovery at scale. Foghorn has advanced multiple candidates into Phase 1 trials and maintains a strategic collaboration with Loxo Oncology at Lilly, positioning it at the forefront of chromatin-based drug discovery.

The proprietary Gene Traffic Control® platform is an integrated system for identifying and drugging targets within the chromatin regulatory system, combining target ID/validation, component production, proprietary assays, and drug discovery/optimization, including targeted protein degradation.

Foghorn competes in the emerging field of chromatin-targeted therapies against companies focused on other epigenetic targets (e.g., EZH2, BET inhibitors). Its key advantages are its systematic platform, deep focus on chromatin remodeling complexes, dual modality strategy (inhibition & degradation), and foundational science from its founders, though it faces competition from larger, resource-rich pharma entrants.